Meeting
2023 ASCO Annual Meeting
Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.
Authors
Lin-Quan Tang
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China
Lin-Quan Tang , Li-Ting Liu , Zhen-Chong Yang , Jia-Yi Shen , Mei-Juan Luo , Ying-Ying Hu , Zi-Jian Lu , Bei-Bei Xiao , Jin-Hao Yang , Xiao-Fei Lv , Guo-Dong Jia , Shan-Shan Guo , Qiu-Yan Chen , Wei Fan , Hai-Qiang Mai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03601390
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6072)
DOI
10.1200/JCO.2023.41.16_suppl.6072
Abstract #
6072
Poster Bd #
64
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
First Author: Mark Charles Korpics
Poster
2023 ASCO Annual Meeting
Radiotherapy alone versus concurrent or adjuvant chemoradiotherapy for nasopharyngeal carcinoma patients with negative Epstein-Barr virus DNA post-induction chemotherapy.
First Author: Fang-Fang Kong
Poster
2023 ASCO Annual Meeting
Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer.
First Author: Kelvin K H Bao
Poster
2022 ASCO Annual Meeting
A phase 1b/2 study of nanatinostat and valganciclovir in patients with advanced Epstein-Barr virus positive (EBV+) solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC).
First Author: A. Dimitrios Colevas